Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (NCT06031688)

🧪 Interventions in This Study

• Ramucirumab (BIOLOGICAL)
• Tepotinib (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Participants must have been assigned to S1900K by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900K is determined by the LUNGMAP protocol
2. Participants must have documentation of stage IV or recurrent NSCLC with a MET exon 14 skipping mutation determined by tissue-based or blood-based (circulating tumor DNA \[ctDNA\]) next generation sequencing (NGS) assay done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)/ International Electrotechnical Commission (IEC), College of American Pathologists (CAP), or similar certification. Documentation must either be:
3. NGS test results from tissue submitted for LUNGMAP screening, or
4. Submitted documentation in the LUNGMAP Rave Electronic Data Capture System of a MET exon 14 skipping mutation from a previously completed tissue or blood-based NGS test
5. Participants must have measurable disease documented by CT or MRI. The CT from a combined positron emission tomography (PET)/CT may be used to document measurable disease ONLY if it is of diagnostic quality, otherwise, it may be used to document non-measurable disease only. Measurable disease must be assessed within 28 days prior to sub-study randomization. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study randomization. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study randomization to be considered measurable
6. Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study randomization
7. Participants must not have leptomeningeal disease, spinal cord compression or brain metastases unless:
8. Metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 3 days following the stereotactic radiation and/or 14 days following whole brain radiation, and prior to sub-study randomization, AND
9. Participant has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to sub-study randomization
10. Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation
11. Participants who have received at least one line of systemic treatment for stage IV or recurrent NSCLC must have progressed (in the opinion of the treating physician) following the most recent line of therapy. Participants who have not yet received systemic treatment for their stage IV or recurrent NSCLC are allowed
12. Participants may have received any number of lines of therapy for stage IV or recurrent NSCLC (including zero) and must be able to report prior treatment information

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (266 Sites)

Showing the first 25 of 266 sites.

• Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
• Thomas Hospital — Fairhope, Alabama
• Mobile Infirmary Medical Center — Mobile, Alabama
• Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland — Saraland, Alabama
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• Kaiser Permanente-Anaheim — Anaheim, California
• Sutter Auburn Faith Hospital — Auburn, California
• Kaiser Permanente-Baldwin Park — Baldwin Park, California
• Kaiser Permanente-Bellflower — Bellflower, California
• Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
• Tower Cancer Research Foundation — Beverly Hills, California
• Kaiser Permanente-Fontana — Fontana, California
• Palo Alto Medical Foundation-Fremont — Fremont, California
• Kaiser Permanente South Bay — Harbor City, California
• Kaiser Permanente-Irvine — Irvine, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
• Kaiser Permanente West Los Angeles — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• Memorial Medical Center — Modesto, California
• Kaiser Permanente-Ontario — Ontario, California
• Palo Alto Medical Foundation Health Care — Palo Alto, California
• Kaiser Permanente - Panorama City — Panorama City, California
• Eisenhower Medical Center — Rancho Mirage, California

📞 Contact the Study Coordinator

Phone: (251) 435-2273

Email: donna.goggins@infirmaryhealth.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Recurrent Lung Non-Small Cell Carcinoma

• Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) — Fairbanks, Alaska
• Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer — Houston, Texas
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) — Daphne, Alabama
• Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer — Scottsdale, Arizona
• NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer — Houston, Texas

Explore by condition: All Recurrent Lung Non-Small Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.